Prevention of Experimental Coronavirus Colds with Intranasal α-2b Interferon
Identifieur interne : 001597 ( Main/Exploration ); précédent : 001596; suivant : 001598Prevention of Experimental Coronavirus Colds with Intranasal α-2b Interferon
Auteurs : Ronald B. Turner [États-Unis] ; Alma Felton [États-Unis] ; Kenneth Kosak [États-Unis] ; Douglas K. Kelsey [États-Unis] ; Carlton K. Meschievitz [États-Unis]Source :
- Journal of Infectious Diseases [ 0022-1899 ] ; 1986.
Abstract
Fifty-five volunteers treated with either intranasal recombinant interferon (rIFN; 2 × 106 IU/day) or placebo for 15 days were exposed to coronavirus by direct intranasal inoculation on the eighth day of treatment. Symptom scores were recorded, and cultures of virus were taken daily for all volunteers for seven days after inoculation. Nineteen (73%) of the 26 placebo recipients met symptom-score criteria for a cold, compared with 12 (41%) of the IFN recipients (P = .02). The mean nasal symptom scores in the placebo and IFN groups were 9.2 and 5.4, respectively (P = .03), and the mean total symptom scores in the two groups were 23.2 and 9.4, respectively (P = .003). The mean number of days with a total symptom score >4 was 1.6 in the placebo recipients and 0.5 in the rIFN recipients (P = .02). Prophylactic intranasal rIFN effectively shortened the duration and reduced the severity of coronavirus cold symptoms.
Url:
DOI: 10.1093/infdis/154.3.443
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000612
- to stream Istex, to step Curation: 000592
- to stream Istex, to step Checkpoint: 000733
- to stream Main, to step Merge: 001621
- to stream Main, to step Curation: 001597
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Prevention of Experimental Coronavirus Colds with Intranasal α-2b Interferon</title><author><name sortKey="Turner, Ronald B" sort="Turner, Ronald B" uniqKey="Turner R" first="Ronald B." last="Turner">Ronald B. Turner</name></author><author><name sortKey="Felton, Alma" sort="Felton, Alma" uniqKey="Felton A" first="Alma" last="Felton">Alma Felton</name></author><author><name sortKey="Kosak, Kenneth" sort="Kosak, Kenneth" uniqKey="Kosak K" first="Kenneth" last="Kosak">Kenneth Kosak</name></author><author><name sortKey="Kelsey, Douglas K" sort="Kelsey, Douglas K" uniqKey="Kelsey D" first="Douglas K." last="Kelsey">Douglas K. Kelsey</name></author><author><name sortKey="Meschievitz, Carlton K" sort="Meschievitz, Carlton K" uniqKey="Meschievitz C" first="Carlton K." last="Meschievitz">Carlton K. Meschievitz</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1D0FF8AED16E7E384980A4C36AB46774636C3254</idno><date when="1986" year="1986">1986</date><idno type="doi">10.1093/infdis/154.3.443</idno><idno type="url">https://api.istex.fr/ark:/67375/HXZ-DJ1QSJD1-H/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000612</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000612</idno><idno type="wicri:Area/Istex/Curation">000592</idno><idno type="wicri:Area/Istex/Checkpoint">000733</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000733</idno><idno type="wicri:doubleKey">0022-1899:1986:Turner R:prevention:of:experimental</idno><idno type="wicri:Area/Main/Merge">001621</idno><idno type="wicri:Area/Main/Curation">001597</idno><idno type="wicri:Area/Main/Exploration">001597</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Prevention of Experimental Coronavirus Colds with Intranasal α-2b Interferon</title><author><name sortKey="Turner, Ronald B" sort="Turner, Ronald B" uniqKey="Turner R" first="Ronald B." last="Turner">Ronald B. Turner</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Departments of Pediatrics and Pathology, University of Utah School of Medicine, Salt Lake City, Utah, Kenilworth</wicri:cityArea></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Utah</region></placeName><wicri:cityArea>Please address requests for reprints to Dr. Ronald B. Turner, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City</wicri:cityArea></affiliation></author><author><name sortKey="Felton, Alma" sort="Felton, Alma" uniqKey="Felton A" first="Alma" last="Felton">Alma Felton</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Departments of Pediatrics and Pathology, University of Utah School of Medicine, Salt Lake City, Utah, Kenilworth</wicri:cityArea></affiliation></author><author><name sortKey="Kosak, Kenneth" sort="Kosak, Kenneth" uniqKey="Kosak K" first="Kenneth" last="Kosak">Kenneth Kosak</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Departments of Pediatrics and Pathology, University of Utah School of Medicine, Salt Lake City, Utah, Kenilworth</wicri:cityArea></affiliation></author><author><name sortKey="Kelsey, Douglas K" sort="Kelsey, Douglas K" uniqKey="Kelsey D" first="Douglas K." last="Kelsey">Douglas K. Kelsey</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Departments of Pediatrics and Pathology, University of Utah School of Medicine, Salt Lake City, Utah, Kenilworth</wicri:cityArea></affiliation></author><author><name sortKey="Meschievitz, Carlton K" sort="Meschievitz, Carlton K" uniqKey="Meschievitz C" first="Carlton K." last="Meschievitz">Carlton K. Meschievitz</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">New Jersey</region></placeName><wicri:cityArea>Departments of Pediatrics and Pathology, University of Utah School of Medicine, Salt Lake City, Utah, Kenilworth</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Infectious Diseases</title><title level="j" type="abbrev">J Infect Dis.</title><idno type="ISSN">0022-1899</idno><idno type="eISSN">1537-6613</idno><imprint><publisher>The University of Chicago Press</publisher><date when="1986-09">1986</date><biblScope unit="vol">154</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="443">443</biblScope><biblScope unit="page" to="447">447</biblScope></imprint><idno type="ISSN">0022-1899</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-1899</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Fifty-five volunteers treated with either intranasal recombinant interferon (rIFN; 2 × 106 IU/day) or placebo for 15 days were exposed to coronavirus by direct intranasal inoculation on the eighth day of treatment. Symptom scores were recorded, and cultures of virus were taken daily for all volunteers for seven days after inoculation. Nineteen (73%) of the 26 placebo recipients met symptom-score criteria for a cold, compared with 12 (41%) of the IFN recipients (P = .02). The mean nasal symptom scores in the placebo and IFN groups were 9.2 and 5.4, respectively (P = .03), and the mean total symptom scores in the two groups were 23.2 and 9.4, respectively (P = .003). The mean number of days with a total symptom score >4 was 1.6 in the placebo recipients and 0.5 in the rIFN recipients (P = .02). Prophylactic intranasal rIFN effectively shortened the duration and reduced the severity of coronavirus cold symptoms.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>New Jersey</li><li>Utah</li></region></list><tree><country name="États-Unis"><region name="New Jersey"><name sortKey="Turner, Ronald B" sort="Turner, Ronald B" uniqKey="Turner R" first="Ronald B." last="Turner">Ronald B. Turner</name></region><name sortKey="Felton, Alma" sort="Felton, Alma" uniqKey="Felton A" first="Alma" last="Felton">Alma Felton</name><name sortKey="Kelsey, Douglas K" sort="Kelsey, Douglas K" uniqKey="Kelsey D" first="Douglas K." last="Kelsey">Douglas K. Kelsey</name><name sortKey="Kosak, Kenneth" sort="Kosak, Kenneth" uniqKey="Kosak K" first="Kenneth" last="Kosak">Kenneth Kosak</name><name sortKey="Meschievitz, Carlton K" sort="Meschievitz, Carlton K" uniqKey="Meschievitz C" first="Carlton K." last="Meschievitz">Carlton K. Meschievitz</name><name sortKey="Turner, Ronald B" sort="Turner, Ronald B" uniqKey="Turner R" first="Ronald B." last="Turner">Ronald B. Turner</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001597 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001597 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:1D0FF8AED16E7E384980A4C36AB46774636C3254
|texte= Prevention of Experimental Coronavirus Colds with Intranasal α-2b Interferon
}}
| This area was generated with Dilib version V0.6.33. |  |